HER2 is well established as a predictive biomarker that can be used to inform therapy decisions in breast cancer patients. This test is commonly performed in a wide variety of labs that handle breast pathology samples however, result information shared on reports back to physicians can vary between
• Different labs
• Paper reports versus electronic reports that are shared using integrated IT systems
Why join the collaboration:
• Help us understand what differences currently exist in HER2 breast reports which may cause delays with patients receiving optimal therapy decisions
As part of this collaboration, you will use our secure DXRX Network to share
1. Requisition form templates that are used by physicians to request a HER2 test for a breast sample
2. HER2 patient report templates that reflect
a. HER2 positive result;
b. HER2 negative result; and
c. HER2 equivocal result including any supplementary reports (e.g. ISH) that provides the physician with a final HER2 result.
Please note: Only upload report templates with no personal data included. To the extent, the reports contain real-life data, you must ensure all information are Anonymized and/or aggregated.
> If the asker cancels more than 1 day(s) before the start of the booking, he is reimbursed 100 % of the amount paid
> If the asker cancels less than 1 day(s) before the start of the booking , he is reimbursed 50 % of the amount paid
As part of this collaboration, you will use our secure DXRX Network to share
1. Requisition form templates that are used by physicians to request a HER2 test for a breast sample
2. HER2 patient report templates that reflect
a. HER2 positive result;
b. HER2 negative result; and
c. HER2 equivocal result including any supplementary reports (e.g. ISH) that provides the physician with a final HER2 result.
Please note: Only upload report templates with no personal data included. To the extent, the reports contain real-life data, you must ensure all information are Anonymized and/or aggregated.